Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated rotavirus vaccine
- Development stage
- Phase 2
- Lead developer
- Centers for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Transdermal
01
Overview
Inactivated rotavirus vaccine (IRV) is a non-replicating, parenterally administered vaccine developed to prevent rotavirus gastroenteritis. Unlike currently licensed oral live-attenuated vaccines, IRVs are produced by chemically or physically inactivating whole rotavirus particles using agents such as formaldehyde, beta-propiolactone, binary ethyleneimine, heat treatment, or ultraviolet irradiation. These methods aim to preserve the antigenic structure of the virus while eliminating infectivity. Preclinical studies have shown that IRVs can induce strong serum antibody responses and mucosal immunity when administered intramuscularly or via microneedle patches. The primary indication for this vaccine is prevention of severe diarrhea caused by rotavirus infection in infants and young children[4][5]. The development of IRV seeks to address safety concerns associated with live oral vaccines and improve efficacy in populations where current vaccines underperform.
- Other names
- IRV
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on Inactivated rotavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inactivated rotavirus vaccine.